| Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma D Chen, SB Le, TE Hutchinson, AA Calinescu, M Sebastian, D Jin, T Liu, ... The Journal of clinical investigation 132 (8), 2022 | 73 | 2022 |
| Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma K Wang, D Chen, Z Qian, D Cui, L Gao, M Lou Cancer Cell International 17, 1-12, 2017 | 61 | 2017 |
| A prospective comparative study of twist drill craniostomy versus burr hole craniostomy in patients with chronic subdural hematoma K Wang, D Chen, X Cao, L Gao Turk Neurosurg 27 (1), 60-65, 2017 | 22 | 2017 |
| Methods for Reducing Viability of Cancer Cells by Activation of the STING Pathway with TTFields D Tran, C Dongjiang US Patent App. 16/673,246, 2021 | 11 | 2021 |
| TSP‐1 is downregulated and inversely correlates with miR‐449c expression in Cushing's disease J Ren, C Gu, Y Yang, J Xue, Y Sun, F Jian, D Chen, L Bian, Q Sun Journal of Cellular and Molecular Medicine 23 (6), 4097-4110, 2019 | 9 | 2019 |
| Ctim-04. Updates for a Phase 2 open-labeled study of pembrolizumab plus Ttfields plus maintenance temozolomide in patients with newly diagnosed glioblastoma (2-the-Top) A Ghiaseddin, S Warren, A Allen, D Sampson, D Chen, A Sherman, ... Neuro-Oncology 22 (Suppl 2), ii33, 2020 | 5 | 2020 |
| Pan-cancer analysis of ASB3 and the potential clinical implications for immune microenvironment of glioblastoma multiforme L Mu, Z Han, S Yu, A Wang, D Chen, S Kong, Y Gu, L Xu, A Liu, R Sun, ... Frontiers in immunology 13, 842524, 2022 | 4 | 2022 |
| IMMU-06. TTFields induces immunogenic cell death and sting pathway activation through cytoplasmic double-stranded DNA in glioblastoma cells D Chen, N Thomas, J Ren, S Le, M Sebstian, C Deng, D Jin, D Tran Neuro-Oncology 21 (Supplement_6), vi120-vi120, 2019 | 3 | 2019 |
| ATIM-39. Phase 2 open-labeled study of adjuvant temozolomide plus tumor treating fields plus pembrolizumab in patients with newly diagnosed glioblastoma (2-THE-TOP) D Tran, S Warren, A Allen, D Sampson, D Chen, N Thomas, V Greene, ... Neuro-Oncology 21 (Suppl 6), vi10, 2019 | 3 | 2019 |
| TTFields induces immunogenic cell death and STING pathway activation through cytoplasmic double-stranded DNA in glioblastoma cells D Chen, N Thomas, J Ren, S Le, M Sebastian, C Deng, D Jin, DD Tran International Journal of Radiation Oncology, Biology, Physics 105 (1), E645, 2019 | 3 | 2019 |
| The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma X Liu, Z Zhao, W Dai, K Liao, Q Sun, D Chen, X Pan, L Feng, Y Ding, ... Cancers 15 (17), 4308, 2023 | 2 | 2023 |
| CTIM-05. Final results of 2-the-top: a pilot phase 2 study of TTfields (OPTUNE) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed … D Tran, A Ghiaseddin, D Chen, S Le, M Rahman Neuro-Oncology 24 (Suppl 7), vii60, 2022 | 1 | 2022 |
| IMMU-42. TTFIELDS INDUCES IMMUNOGENIC CELL DEATH AND STING PATHWAY ACTIVATION THROUGH CYTOPLASMIC DOUBLE-STRANDED DNA IN GBM D Chen, N Thomas, J Ren, S Le, C Deng, D Jin, M Sebastian, D Nguyen, ... Neuro-Oncology 20 (Suppl 6), vi130, 2018 | 1 | 2018 |
| Snail1 regulates the tumor-infiltrating regulatory T cell population in breast cancer through Pglyrp3 D Chen, M Sebastian, S Le, N Thomas, DD Tran Cancer Research 78 (13_Supplement), 4748-4748, 2018 | 1 | 2018 |
| Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy T Liu, D Jin, SB Le, D Chen, M Sebastian, A Riva, R Liu, DD Tran Cancer Immunology Research, OF1-OF21, 2024 | | 2024 |
| In Vivo Mouse Models for Adult Brain Tumors: Exploring Tumorigenesis and Advancing Immunotherapy Development J Figg, D Chen, L Falceto Font, C Flores, D Jin Neuro-Oncology, noae131, 2024 | | 2024 |
| Blocking Immune Checkpoint—LAIR1: Disrupting the LAIR1—FXIII-A—Collagen Immunosuppressive Circuit for Enhanced Antitumor Therapeutics J Huang, H Tao, D Chen, C Yang, D Nguyen, R Liu, T Liu, A Chakraborty, ... | | 2024 |
| Methods for restoring sensitivity to TTFields in TTFields-resistant cancer cells with PTGER3 inhibitors D Tran, SB Le, C Dongjiang US Patent 11,911,610, 2024 | | 2024 |
| FATE-BASED CONVERSION FOR IN SITU VACCINATION IN GLIOBLASTOMA D Tran, T Liu, D Jin, S Le, D Chen NEURO-ONCOLOGY 25, 2023 | | 2023 |
| FINAL EFFICACY AND CORRELATIVE ANALYSES OF 2-THE-TOP: A PILOT STUDY OF TTFIELDS (OPTUNE) PLUS PEMBROLIZUMAB PLUS MAINTENANCE TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED … D Tran, D Chen, S Le, A Ghiaseddin NEURO-ONCOLOGY 25, 2023 | | 2023 |
